Juventas Therapeutics, Inc.
Founded on intellectual property exclusively licensed from the Cleveland Clinic, Juventas Therapeutics is developing an innovative regenerative medicine product named JVS-100. JVS-100 is a plasmid that encodes Stromal Cell-derived Factor-1 (SDF-1), which is a naturally-occurring chemokine (guide for migration of cells) that is rapidly over-expressed in response to tissue injury.
The Company’s unique approach to treating heart disease has the potential to treat the damaged heart and increase blood flow while being much simpler and less expensive than current stem-cell based treatments. The Company is currently in clinical development of JVS-100 to promote non-cell based regenerative healing of patients with chronic heart failure. The Company is also beginning clinical trials for the use of JVS-100 to treat critical limb ischemia (CLI).
Juventas was founded by Marc Penn, M.D., Ph.D., who is responsible for having identified several factors involved in the repair process, including SDF-1.